Humanity & Health

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Shiv Kumar Sarin, Manoj Kumar, George Lau et al. · Hepatology International · 2015 · 2.5K citations · Full text

Hepatitis B, Previous Apasl Guidelines, Autoimmune Liver Disease +16

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.3K citations · Full text

Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score

Dong Ji, Dawei Zhang, Jing Xu et al. · Clinical Infectious Diseases · 2020 · 712 citations · Full text

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2022 · 390 citations

First-line Therapy, Psychotropic Medication, Pathology +25

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Shiv Kumar Sarin, Ashok Choudhury, George Lau et al. · Hepatology International · 2020 · 293 citations · Full text

Hepatology, Sars Cov2 Infection, Apcolis Study +10